Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12608000447358
Ethics application status
Approved
Date submitted
20/08/2008
Date registered
8/09/2008
Date last updated
8/09/2008
Type of registration
Retrospectively registered
Titles & IDs
Public title
Pravastatin in Polycystic Kidney Disease
Query!
Scientific title
Effect of Pravastatin on Kidney Function in Polycystic Kidney Disease
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Polycystic Kidney Disease
3585
0
Query!
Condition category
Condition code
Renal and Urogenital
3745
3745
0
0
Query!
Kidney disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Pravastatin 20mg orally daily for 2 years
Query!
Intervention code [1]
3301
0
Treatment: Drugs
Query!
Comparator / control treatment
Control group with no treatment
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
4644
0
Serum Creatinine (blood analysis)
Query!
Assessment method [1]
4644
0
Query!
Timepoint [1]
4644
0
every 3 months for 2 years
Query!
Secondary outcome [1]
7852
0
Proteinuria measured by 24 hour urine collection
Query!
Assessment method [1]
7852
0
Query!
Timepoint [1]
7852
0
every 3 months for 2 years
Query!
Eligibility
Key inclusion criteria
Polycystic kidney disease
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
85
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Females of Child bearing potential
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Patients screened and identified as having polycystic kidney disease attending the nephrologists clinics offered enrollment
Independent central co-ordinator performs randomization from computer generated random numbers placed in concealed envelopes
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer generated random numbers
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3 / Phase 4
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
1/01/1998
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
100
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Funding source category [1]
3761
0
Charities/Societies/Foundations
Query!
Name [1]
3761
0
Clifford Craig Medical Research Trust
Query!
Address [1]
3761
0
Launceston General Hospital
Charles St, Launceston, 7250
Query!
Country [1]
3761
0
Australia
Query!
Primary sponsor type
Charities/Societies/Foundations
Query!
Name
Clifford Craig Medical Research Trust
Query!
Address
Launceston General Hospital
Charles St, Launceston, 7250
Query!
Country
Australia
Query!
Secondary sponsor category [1]
3362
0
None
Query!
Name [1]
3362
0
Query!
Address [1]
3362
0
Query!
Country [1]
3362
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
5821
0
Epworth Research and Ethics Committee
Query!
Ethics committee address [1]
5821
0
Epworth Medical Centre 185-187 Hoddle Street Richmond, VIV, 3121
Query!
Ethics committee country [1]
5821
0
Australia
Query!
Date submitted for ethics approval [1]
5821
0
Query!
Approval date [1]
5821
0
11/02/1997
Query!
Ethics approval number [1]
5821
0
9096S
Query!
Summary
Brief summary
Polycystic kidney disease is a common cause of kidney failure Statins may slow kidney disease progression. This study aimed to assess whether pravastatin 20mg could slow the progression of kidney disease
Query!
Trial website
Nil
Query!
Trial related presentations / publications
Nil
Query!
Public notes
Query!
Contacts
Principal investigator
Name
28854
0
Query!
Address
28854
0
Query!
Country
28854
0
Query!
Phone
28854
0
Query!
Fax
28854
0
Query!
Email
28854
0
Query!
Contact person for public queries
Name
12011
0
Professor Robert Fassett
Query!
Address
12011
0
Renal Research Tasmania
Launceston General Hospital
Charles Street
Launceston
Tasmania
Query!
Country
12011
0
Australia
Query!
Phone
12011
0
0419399571
Query!
Fax
12011
0
0363487577
Query!
Email
12011
0
[email protected]
Query!
Contact person for scientific queries
Name
2939
0
Professor Robert Fassett
Query!
Address
2939
0
Renal Research Tasmania
Launceston
Charles Street
Launceston Tasmania
Query!
Country
2939
0
Australia
Query!
Phone
2939
0
0419399571
Query!
Fax
2939
0
0363487577
Query!
Email
2939
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF